BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 30

• 

  Sruthi S. Balakrishnan

  Sruthi S. Balakrishnan is a freelance academic editor, science writer and fact-checker based in Santa Barbara, California. She can be reached at sruthisb@sciscriber.com.
• 

  Wacker Biotech
• 

  FDA

  FDA Adcomm Recommends Limiting Keytruda, Opdivo Use in Stomach, Esophageal Cancer

  The FDA’s Oncology Drugs Advisory Committee voted near-unanimously that the benefits of PD-1 inhibitors like Keytruda and Opdivo in PD-L1 low patients do not outweigh the risks.

  September 27, 2024

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Parkinson’s disease

  AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win

  Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.

  September 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Alzheimer’s disease

  Cassava Agrees to Pay $40M Fine to Resolve SEC Probe as Company Hit With New Lawsuit

  Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District Court of Texas, claiming that the company misled investors regarding the Phase IIb performance of its Alzheimer’s disease drug candidate.

  September 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Editorial

  Lilly Is Not ‘Feeling the Bern’ on Drug Prices Like Novo: Why the Double Standard?

  Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s rival drugs, is not fair.

  September 27, 2024

   · 

  3 min read

   · 

  Greg Slabodkin
• 

  FDA

  Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD

  Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.

  September 27, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Immunology and inflammation

  Roche Looks to Push Gazyva Into Lupus Nephritis With Promising Late-Stage Data

  In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis versus placebo, positioning Roche’s therapeutic antibody for expansion into the indication.

  September 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Sickle Cell Disease

  Pfizer’s Oxbryta Withdrawal Leaves Sickle Cell Community Scrambling, Investors Reeling

  Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in sales by the end of the decade, has left patients and healthcare providers with few options, while investors question the pharma giant’s dealmaking prowess.

  September 27, 2024

   · 

  7 min read

   · 

  Annalee Armstrong
• 

  Schizophrenia

  FDA Approves First Novel Schizophrenia Drug in 35 Years

  BMS’ KarXT targets muscarinic receptors and “is at least 2-3 years ahead of the competition” including AbbVie and Neurocrine Biosciences, Truist Securities wrote in a note to investors.

  September 27, 2024

   · 

  8 min read

   · 

  Heather McKenzie